Efficacy of a Multi-Strain Probiotic Formulation in Pediatric Populations: A Comprehensive Review of Clinical Studies.

ABSTRACT: A probiotic formulation combining Lactobacillus helveticus Rosell^®-52, Bifidobacterium infantis Rosell^®-33, and Bifidobacterium bifidum Rosell^®-71 with fructooligosaccharides, first commercialized in China, has been sold in over 28 countries since 2002. Clinical studies with this blend of strains were conducted mainly in pediatric populations, and most were published in non-English journals. This comprehensive review summarizes the clinical studies in infants and children to evaluate the efficacy of this probiotic for pediatric indications. Literature searches for pediatric studies on Biostime^® or Probiokid^® (non-commercial name) in 6 international and Chinese databases identified 28 studies, which were classified

SUBMITTER: Tremblay A 

PROVIDER: S-EPMC8226750 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature